{"id":53971,"date":"2023-02-15T22:05:41","date_gmt":"2023-02-15T21:05:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/"},"modified":"2023-02-15T22:05:41","modified_gmt":"2023-02-15T21:05:41","slug":"immunogen-announces-conference-call-to-discuss-its-2022-operating-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/","title":{"rendered":"ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results"},"content":{"rendered":"
\n

WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen Inc.<\/a> (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Wednesday, March 1, 2023 to discuss its 2022 operating results. Management will also provide a brief update on the business.\n<\/p>\n

<\/a><\/p>\n

\nCONFERENCE CALL INFORMATION
\n
<\/b>To access the live call by phone, please register here<\/a>. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company\u2019s website, www.immunogen.com<\/a>. Following the call, a replay will be available at the same location.\n<\/p>\n

\nABOUT IMMUNOGEN
\n
<\/b>ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW\u2122.\n<\/p>\n

\nLearn more about who we are, what we do, and how we do it at www.immunogen.com.<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nINVESTOR RELATIONS<\/b>
ImmunoGen
\n
Anabel Chan
\n
781-895-0600
\n
anabel.chan@immunogen.com<\/a>\n<\/p>\n

\nMEDIA<\/b>
ImmunoGen
\n
Courtney O’Konek
\n
781-895-0600
\n
courtney.okonek@immunogen.com<\/a>\n<\/p>\n

\nOR\n<\/p>\n

\nFTI Consulting
\n
Robert Stanislaro
\n
212-850-5657
\n
robert.stanislaro@fticonsulting.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Wednesday, March 1, 2023 to discuss its 2022 operating results. Management will also provide a brief update on the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53971","6":"format-standard","7":"category-industry"},"yoast_head":"\nImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Wednesday, March 1, 2023 to discuss its 2022 operating results. Management will also provide a brief update on the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-15T21:05:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230215005231\/en\/1713949\/21\/imgnlogo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results\",\"datePublished\":\"2023-02-15T21:05:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\\\/\"},\"wordCount\":229,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230215005231\\\/en\\\/1713949\\\/21\\\/imgnlogo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\\\/\",\"name\":\"ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230215005231\\\/en\\\/1713949\\\/21\\\/imgnlogo.jpg\",\"datePublished\":\"2023-02-15T21:05:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230215005231\\\/en\\\/1713949\\\/21\\\/imgnlogo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230215005231\\\/en\\\/1713949\\\/21\\\/imgnlogo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/","og_locale":"en_US","og_type":"article","og_title":"ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results - Pharma Trend","og_description":"WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Wednesday, March 1, 2023 to discuss its 2022 operating results. Management will also provide a brief update on the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-15T21:05:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230215005231\/en\/1713949\/21\/imgnlogo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results","datePublished":"2023-02-15T21:05:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/"},"wordCount":229,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230215005231\/en\/1713949\/21\/imgnlogo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/","url":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/","name":"ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230215005231\/en\/1713949\/21\/imgnlogo.jpg","datePublished":"2023-02-15T21:05:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230215005231\/en\/1713949\/21\/imgnlogo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230215005231\/en\/1713949\/21\/imgnlogo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/immunogen-announces-conference-call-to-discuss-its-2022-operating-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ImmunoGen Announces Conference Call to Discuss Its 2022 Operating Results"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53971"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53971\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}